At Fox Chase Cancer Center and Temple Health, liver cancer research and treatment have long been a focus. Primary liver cancer, also called hepatocellular carcinoma (HCC), is the fifth most common cancer in the world. It is accompanied in most cases by underlying disease such as cirrhosis, which features extensive scarring of the liver. The most common causes of cirrhosis and HCC worldwide are viral hepatitis B and C.
Medical excellence was top of mind for Temple Health donors this year, whose combined philanthropic support of education, patient care, research and service to the community totaled an impressive $52.5 million—$25.5 million raised for the Lewis Katz School of Medicine, $16.8 million for Fox Chase Cancer Center and $10.2 million for Temple University Hospital.
Among the many changes that cancer and its treatment bring, perhaps none is more challenging than cachexia (pronounced “kuh-KEK-see-uh”), a wasting syndrome in which patients experience loss of body fat and muscle as a result of advanced cancer or malnourishment.
At the forefront of this pandemic have been nurses who, day in and day out, are charged with not only caring for the physical health and mental well-being of their patients, but also with an immeasurable amount of behind-the-scenes work that ensures that operations run smoothly.
Every three minutes, someone in the United States is diagnosed with a blood cancer. These cancers, which include leukemia, lymphoma, multiple myeloma, and many others, account for nearly 10% of all new cancer cases, according to the Leukemia Research Foundation. The Leukemia and Lymphoma Society estimates that 1.3 million Americans are living with, or are in remission from, leukemia, lymphoma, or myeloma.